CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

50 mg/mL VirazoleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug5 100 mg/mL Virazole Wiki 1.00
drug26 ATV Wiki 1.00
drug207 Cobicistat Wiki 1.00
drug245 DRV Wiki 1.00
drug102 BR Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D000163 Acquired Immunodeficiency Syndrome NIH 1.00
D015658 HIV Infections NIH 1.00
D007153 Immunologic Deficiency Syndromes NIH 0.71

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002721 Immunodeficiency HPO 1.00

There is one clinical trial.

Clinical Trials

1 An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

This study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result, have significant respiratory distress (PaO2/FiO2 ratio <300 mmHg).

NCT04356677 COVID19 Drug: 50 mg/mL Virazole Drug: 100 mg/mL Virazole

Primary Outcomes

Description: The severity rating will be based on the ordinal scale of clinical status as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.

Measure: Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment

Time: 7 days

Secondary Outcomes

Measure: Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.

Time: 7 days

Measure: Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.

Time: 7 days

No related HPO nodes (Using clinical trials)